Pranjal Sharma

Dr. Pranjal Sharma

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GDGagandeep Dhillon
Gagandeep Dhillon
VBVenkata Buddhavarapu
Venkata Buddhavarapu
HGHarpreet Grewal
Harpreet Grewal
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
Rahul KashyapRahul Kashyap
Rahul Kashyap
Hydrogen-rich water (HRW) has emerged as a novel approach in the field of health and wellness. It is believed to have therapeutic antioxidant properties that can neutralize harmful free radicals in the human body. It has also been shown to be beneficial in mitigating oxidative stress-induced damage through its anti-inflammatory and anti-apoptotic pathways. We aim to conduct a systematic review to evaluate the potential benefits of hydrogen-rich water. The review protocol was uploaded on PROSPERO. After the initial search criteria, the articles were reviewed by two blinded investigators, and a total of 25 articles were included in the systematic review. The potential benefits of hydrogen-rich water on various aspects of health, including exercise capacity, physical endurance, liver function, cardiovascular disease, mental health, COVID-19, oxidative stress, and anti-aging research, are a subject of growing interest and ongoing research. Although preliminary results in clinical trials and studies are encouraging, further research with larger sample sizes and rigorous methodologies is needed to substantiate these findings. Current research needs to fully explain the mechanisms behind the potential benefits of hydrogen-rich water. Continued scientific exploration will provide valuable insights into the potential of hydrogen-rich water as an adjunctive therapeutic approach in the future.

11 September 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Rakhtan K. QasbaRakhtan K. Qasba
Rakhtan K. Qasba
ABAnna Carolina Flumignan Bucharles
Anna Carolina Flumignan Bucharles
MPMaria Victória Ferreira Piccoli
Maria Victória Ferreira Piccoli
PSPranjal Sharma
Pranjal Sharma
Akshat BangaAkshat Banga
Akshat Banga
Rahul KashyapRahul Kashyap
Rahul Kashyap
Background and Objectives: Bartter syndrome (BS) is a rare group of autosomal-recessive disorders that usually presents with hypokalemic metabolic alkalosis, occasionally with hyponatremia and hypochloremia. The clinical presentation of BS is heterogeneous, with a wide variety of genetic variants. The aim of this systematic review was to examine the available literature and provide an overview of the case reports and case series on BS. Materials and Methods: Case reports/series published from April 2012 to April 2022 were searched through Pubmed, JSTOR, Cochrane, ScienceDirect, and DOAJ. Subsequently, the information was extracted in order to characterize the clinical presentation, laboratory results, treatment options, and follow-up of the patients with BS. Results: Overall, 118 patients, 48 case reports, and 9 case series (n = 70) were identified. Out of these, the majority of patients were male (n = 68). A total of 21 patients were born from consanguineous marriages. Most cases were reported from Asia (73.72%) and Europe (15.25%). In total, 100 BS patients displayed the genetic variants, with most of these being reported as Type III (n = 59), followed by Type II (n = 19), Type I (n = 14), Type IV (n = 7), and only 1 as Type V. The most common symptoms included polyuria, polydipsia, vomiting, and dehydration. Some of the commonly used treatments were indomethacin, potassium chloride supplements, and spironolactone. The length of the follow-up time varied from 1 month to 14 years. Conclusions: Our systematic review was able to summarize the clinical characteristics, presentation, and treatment plans of BS patients. The findings from this review can be effectively applied in the diagnosis and patient management of individuals with BS, rendering it a valuable resource for nephrologists in their routine clinical practice.

1 August 2024 in Endocrines
Verified
Journal Article
Open access
PDF file
PSPranjal Sharma
Pranjal Sharma
VBVenkata Buddhavarapu
Venkata Buddhavarapu
GDGagandeep Dhillon
Gagandeep Dhillon
RVRam Kishun Verma
Ram Kishun Verma
RDRamprakash Devadoss
Ramprakash Devadoss
Rahul KashyapRahul Kashyap
Rahul Kashyap
As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and associations are unclear regarding some of them. We performed a systematic review of studies related to GLP-1 RA drugs. Drugs that have been the subject of at least three studies meeting all our criteria were included. Analysis of GLP-1 RA therapies across eight studies, involving 4422 subjects, indicated varying rates of Serious Adverse Events (SAEs). Semaglutide demonstrated an SAE incidence of 8.9%, compared to 6.2% for Liraglutide. These results were not statistically significant. For both drugs, no clear association with pancreatitis or neoplasm was established. Discontinuation rates due to adverse effects were 10.3% for Semaglutide and 8.3% for Liraglutide. Severe adverse effects with GLP-1 RA use are not uncommon, and warrant further close monitoring when patients are started on treatment. Further studies are required to analyze the difference between the adverse effect profiles of each drug and to assess whether or not each of these severe adverse effects is dose dependent.

3 September 2023 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
GDGagandeep Dhillon
Gagandeep Dhillon
HGHarpreet Grewal
Harpreet Grewal
VMVarun Monga
Varun Monga
RMRipudaman Singh Munjal
Ripudaman Singh Munjal
VBVenkata S. Buddhavarapu
Venkata S. Buddhavarapu
RKRahul Kashyap
Rahul Kashyap

Verified
Journal Article
Open access
PDF file
RDRamprakash Devadoss
Ramprakash Devadoss
GDGagandeep Dhillon
Gagandeep Dhillon
PSPranjal Sharma
Pranjal Sharma
RVRam Kishun Verma
Ram Kishun Verma
RMRipudaman Singh Munjal
Ripudaman Singh Munjal
Rahul KashyapRahul Kashyap
Rahul Kashyap
Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure demands a multidisciplinary approach, encompassing medications, lifestyle modifications, and often medical devices or surgeries. The treatment burden is substantial, impacting patients’ daily lives and straining healthcare systems. Improving early detection, novel therapies, and patient education are crucial for alleviating the burden and enhancing the quality of life. There are notable advancements in the field of heart failure treatment and prevention. We will discuss significant pharmacological and device advances related to heart failure, including angiotensin receptor–neprilysin inhibitor, sodium–glucose co-transporter inhibition, glucagon-like peptide-1 agonist, cardiac resynchronization therapy, cardiac contractility modulation, mechanical circulatory support devices, and transcatheter valve interventions. We will also review novel therapies on the horizon, emerging technologies like CRISPR-based treatments for genetic anomalies, and the involvement of artificial intelligence in heart failure detection and management.

26 March 2024 in Cureus
Verified
Journal Article
Open access
PDF file
PSPranjal Sharma
Pranjal Sharma
CJCarmen Julius
Carmen Julius
HLHerlitz Leal
Herlitz Leal
RMRipudaman S. Munjal
Ripudaman S. Munjal
GDGagandeep Dhillon
Gagandeep Dhillon
RKRahul Kashyap
Rahul Kashyap
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) is a relatively rare diagnosis with variable presentation. When detectable, the disease is typically indolent rather than malignant and recurs in transplant cases. Here, we report a case of PGNMID, which presented clinically as rapidly progressive glomerulonephritis (RPGN). The patient presented to his primary care physician’s office with diarrhea for one day and was admitted for acute kidney injury. Urine sediment was active, and the patient had nephrotic range proteinuria. Serologic workup was negative for any monoclonality: ANA, c-ANCA, and p-ANCA. Kidney biopsy showed diffuse proliferative and crescentic glomerulonephritis with IgG3-kappa restricted deposits, consistent with PGNMID. The patient required dialysis initiation, and corticosteroids were administered. The patient declined further immunomodulatory treatment and remains hemodialysis-dependent. This case highlights the potential for severe renal damage from monoclonal proteins despite an indolent or even undetectable hematologic clone. This entity needs further studies to better understand its immuno-physiological background and develop a standard treatment regimen.